Enantone 1-Month DPS 3.75 mg/Enantone 3-Month DPS 11.25 mg/Enantone 6-Month DPS 30 mg Drug Interactions

Enantone 1-Month DPS 3.75 mg: Endometriosis, Uterine myoma: Precautions for coadministration: ENANTONE should be administered with care when coadministered with the following drugs. (See Table 18.)

Click on icon to see table/diagram/image

Enantone 3-Month DPS 11.25 mg: Since androgenic deprivation treatment may prolong the QT interval, the concomitant use of Enantone with medicinal products known to prolong the QT interval or associated with Torsades de Pointes, such as class IA antiarrhythmic medicinal products (e.g. quinidine, disopyramide) or class III ones (e.g. amiodarone, sotalol, dofetilide, ibutilide), methadone, moxifloxacin and antipsychotics should be carefully investigated (see Precautions).
Enantone 6-Month DPS 30 mg: Since androgen deprivation treatment may prolong the QT interval, the concomitant use of ENANTONE 6 MONTH DPS with medicinal products known to prolong the QT interval or medicinal products able to induce Torsade de pointes such as class IA (e.g. quinidine, disopyramide) or class III (e.g. amiodarone, sotalol, dofetilide, ibutilide) antiarrhythmic medicinal products, methadone, moxifloxacin, antipsychotics, etc. should be carefully evaluated (see Precautions).